Clinical Trial Update: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer [Phase 1]

View source ↗

Summary

This update reports termination of a Phase 1 study evaluating lapatinib in combination with Caelyx for advanced HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: HER-2 Positive Breast Cancer, Malignant Neoplasm of Breast | Phase 1 | Status: TERMINATED